Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 11/20 | 0.79 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.79 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.35 |
| ▸ | RXRA | P19793 | 2/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.32 |
| ▸ | MAOB | P27338 | 2/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5383448 | 1.00 | ERBB2 (0.79) | ERBB2MINK1HMOX1RXRANR1H2 | |
| SCHEMBL28469047 | 0.98 | ERBB2 (0.75) | ERBB2MINK1HMOX1RXRANR1H2 | |
| SCHEMBL22398126 | 0.98 | ERBB2 (0.75) | ERBB2MINK1HMOX1RXRANR1H2 | |
| SCHEMBL22398129 | 0.92 | ERBB2 (0.66) | ERBB2MINK1NOS1 | |
| SCHEMBL22398356 | 0.91 | ERBB2 (0.65) | ERBB2MINK1 | |
| SCHEMBL28469726 | 0.91 | ERBB2 (0.65) | ERBB2MINK1 | |
| SCHEMBL5522034 | 0.91 | ERBB2 (0.69) | ERBB2MINK1MAPTFFAR1 | |
| SCHEMBL5522038 | 0.91 | ERBB2 (0.69) | ERBB2MINK1MAPTFFAR1 | |
| SCHEMBL31130626 | 0.91 | ERBB2 (0.69) | ERBB2MINK1MAPTFFAR1 | |
| SCHEMBL6582276 | 0.91 | ERBB2 (0.68) | ERBB2MINK1MAPTFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7247649-B2 | Oxazoles, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2007-07-24 | — | — | US | claimed |
| CN-1835947-A | Novel oxazoles, their preparation and use as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 2006-09-20 | — | — | CN | claimed |
| EP-1656371-A2 | NOVEL OXAZOLES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-17 | — | — | EP | claimed |
| WO-2005016921-A2 | NOVEL OXAZOLES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-24 | — | — | WO | claimed |
| US-20050038091-A1 | Novel oxazoles, their manufacture and use as pharmaceutical agents | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-17 | — | — | US | claimed |
| CN-111886234-B | Heterocyclic mitochondrial activity inhibitors and uses thereof | 蒙特利尔大学 | 2023-12-15 | — | — | CN | disclosed |
| US-20230357221-A1 | HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF | UNIV MONTREAL (CA) | 2023-11-09 | — | — | US | disclosed |
| US-11760754-B2 | Heterocyclic mitochondrial activity inhibitors and uses thereof | Université de Montréal (CA) | 2023-09-19 | — | — | US | disclosed |
| US-11760754-B2 | Heterocyclic mitochondrial activity inhibitors and uses thereof | Université de Montréal (CA) | 2023-09-19 | — | — | US | disclosed |
| US-20210387980-A1 | HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF | Université de Montréal (CA) | 2021-12-16 | — | — | US | disclosed |
| CN-111886234-A | Heterocyclic mitochondrial activity inhibitors and uses thereof | 蒙特利尔大学 | 2020-11-03 | — | — | CN | disclosed |
| EP-3704111-A1 | HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF | Université de Montréal (CA) | 2020-09-09 | — | — | EP | disclosed |
| US-7247649-B2 | Oxazoles, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2007-07-24 | — | — | US | disclosed |
| CN-1835947-A | Novel oxazoles, their preparation and use as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 2006-09-20 | — | — | CN | disclosed |
| EP-1656371-A2 | NOVEL OXAZOLES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-17 | — | — | EP | disclosed |
| WO-2005016921-A2 | NOVEL OXAZOLES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-24 | — | — | WO | disclosed |
| US-20050038091-A1 | Novel oxazoles, their manufacture and use as pharmaceutical agents | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357221-A1 | HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF | IDH2, TFAM, IDH1 | ERBB2 2558/4885MINK1 1781/4885HMOX1 1334/4885 |
| US-20050038091-A1 | Novel oxazoles, their manufacture and use as pharmaceutical agents | OXA1L, CYP11B2, RORB | ERBB2 944/4885MINK1 1364/4885HMOX1 327/4885 |
| US-20210387980-A1 | HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF | IDH2, TFAM, NUTF2 | ERBB2 2443/4885MINK1 1986/4885HMOX1 1433/4885 |
| US-11760754-B2 | Heterocyclic mitochondrial activity inhibitors and uses thereof | IDH2, TFAM, NUTF2 | ERBB2 2443/4885MINK1 1986/4885HMOX1 1433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.